

## Match Overview

|   |  |     |
|---|--|-----|
| 1 | Internet 33 words<br>crawled on 09-Jul-2019<br><a href="https://f6publishing.blob.core.windows.net">f6publishing.blob.core.windows.net</a>               | 1%  |
| 2 | Internet 16 words<br>crawled on 23-May-2019<br><a href="https://academic.oup.com">academic.oup.com</a>   | <1% |
| 3 | Crossref 13 words<br><a href="#">Peter Hoffmann, Johannes Krisam, Wolfgang Stremmel, Annika Gauss. "Real-World Outcomes of Vedolizumab Therapy   ...</a> | <1% |

<sup>1</sup>  
Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 48969

Manuscript Type: ORIGINAL ARTICLE

*Retrospective Study*

Ustekinumab: 'Real-world' outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease

Hoffmann P *et al.* 'Real-world' performance of ustekinumab

Peter Hoffmann, Johannes Krisam, Cyrill Wehling, Petra Kloeters-Plachky, Yvonne Leopold, Nina Belling, Annika Gauss





国内版 国际版

Ustekinumab: 'Real-world' outcomes and potential predictors of nonresponse in ti



All Images Videos

翻译成中文

关闭取词

12,200 Results

Any time ▾

## Clinical, endoscopic and radiographic outcomes with ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14016>

To assess the **real-world** clinical, endoscopic and radiographic response and remission **outcomes** achieved with **ustekinumab** in medically-refractory CD. Methods A retrospective multicentre cohort study was performed on CD patients receiving **ustekinumab** between 2011 and 2016.

Cited by: 31 Author: C. Ma, R. N. Fedorak, G. G. Kaplan, L. A...

Publish Year: 2017

## Ustekinumab for the Treatment of Refractory Crohn's ...

<https://academic.oup.com/ibdjournal/article/22/7/1662/4562007> ▾

Jun 10, 2016 - The response to ustekinumab therapy was the dependent variable, whereas the independent variables were sex, smoking, disease duration, history of **bowel resection**, previous **medication**, concomitant therapy, CRP level at baseline, and initial response.

Cited by: 70 Author: Sam Khorrami, Daniel Ginard, Ignacio M...

Publish Year: 2016 Author: Khorrami, Sam

## [Full text] Clinical utility of ustekinumab in Crohn's ...

<https://www.dovepress.com/clinical-utility-of-ustekinumab-in-crohns-disease-peer...> ▾

Nov 17, 2017 - Clinical utility of ustekinumab in **Crohn's disease**. Ustekinumab (UST) is a fully human IgG1κ monoclonal antibody that inhibits the p40 subunit shared by the proinflammatory cytokines, the **interleukin** (IL)-12 and -23. This blockade leads to dampening of the inflammatory cascade and differentiation of inflammatory T cells.

Cited by: 2 Author: Paulo Gustavo Kotze, Christopher Ma, A...

Publish Year: 2018

## Ustekinumab Induction and Maintenance Therapy in ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1203572>

Oct 18, 2012 - In patients with **Crohn's disease**, the efficacy of **ustekinumab**, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown. We evaluated **ustekinumab** ...

Cited by: 720 Author: William J. Sandborn, Christopher Gasink,...

Publish Year: 2012

## Ustekinumab Is Effective for the Treatment of Crohn's ...

<https://academic.oup.com/ibdjournal/article/25/4/767/5117247> ▾

<https://cn.bing.com/?FORM=Z9FD1> A recent network analysis suggested that **ustekinumab** is the preferred **second-line** ...

## Ustekinumab

Common brand name: Stelara

Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis, or a certain bowel condition.

## Precautions



Side Effects



Interactions



Warnings

**Pregnancy category:** Consult a doctor

**Availability:** Prescription needed

**Drug classes:** Immunological Agent · Interleukin inhibitors

**Brand names:** [Stelara](#) · [Stelara PFS](#)

**May treat:** [Crohn's disease](#) · [Psoriatic arthritis](#) · [Psoriasis](#)

## People also search for

[Adalimumab](#)

[Vedolizumab](#)

[Infliximab](#)

[Etanercept](#)

[Golimumab](#)

[See more](#) ▾

Consult a medical professional for advice.

Data from: [First Databank](#) · [Wikipedia](#) · [NIH](#) · [Drugs](#) · [Freebase](#)

[Suggest an edit](#)



[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 4,530 条结果 (用时 0.50 秒)

## Google 学术: Ustekinumab: 'Real-world' outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease

... year in patients with active inflammatory bowel disease ... - Stallmach - 被引用次数: 69

... in the management of inflammatory bowel diseases - Castele - 被引用次数: 76

... 23 (IL23) for the treatment of Crohn's disease - Ma - 被引用次数: 4

## Clinical utility of ustekinumab in Crohn's disease - NCBI

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810512/> ▼ [翻译此页](#)

作者: PG Kotze - 2018 - 被引用次数: 5 - [相关文章](#)

2018年2月8日 - Real-world evidence has further defined the role of UST in CD management. ... targets for treatment are required for these patients with refractory disease. .... With respect to secondary induction outcomes, clinical remission at week 6 ..... Potential predictors of UST response in univariate and multivariate ...

## CLINICAL POSTERS P-019 to P-123 | The American Journal of ...

<https://www.nature.com> › [the american journal of gastroenterology](#) › [abstract](#) - [翻译此页](#)

2018年2月14日 - P-019 Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves .... P-023 Vedolizumab for the Treatment of Refractory Microscopic ColitisP-023 .... RESULTS: A 49 year old female with known Crohn's disease presented ..... CONCLUSION(S): In real-world clinical practice, patients treated with VDZ ...

## Abstracts 2018 - ECCO IBD

<https://www.ecco-ibd.eu/publications/congress-abstract.../abstracts-2018.html> ▼ [翻译此页](#)

... show potential to treat fibrosis and stenosis associated with inflammatory bowel ... predict outcome



国内版 国际版

Ustekinumab: 'Real-world' outcomes and potential predictors of nonresponse in t



All

Images

Videos

翻译成中文

关闭取词

12,200 Results

Any time ▼

## Ustekinumab Induction and Maintenance Therapy in ...

<https://www.nejm.org/doi/full/10.1056/NEJMoa1203572>

Oct 18, 2012 · In patients with Crohn's disease, the efficacy of **ustekinumab**, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown. We evaluated **ustekinumab** ...

Cited by: 720

Author: William J. Sandborn, Christopher Gasink,...

Publish Year: 2012

## [Full text] Clinical utility of ustekinumab in Crohn's ...

<https://www.dovepress.com/clinical-utility-of-ustekinumab-in-crohns-disease-peer...> ▼

Nov 17, 2017 · Potential predictors of UST response in univariate and multivariate models derived from observational cohorts have been inconsistent, and regression model power has been generally limited by small sample size. ... endoscopic and radiographic **outcomes** with **ustekinumab** in medically-refractory Crohn's disease: real world experience from a ...

Cited by: 2

Author: Paulo Gustavo Kotze, Christopher Ma, A...

Publish Year: 2018

## Clinical, endoscopic and radiographic outcomes with ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14016>

To assess the **real-world** clinical, endoscopic and radiographic response and remission **outcomes** achieved with **ustekinumab** in medically-refractory CD. Methods A retrospective multicentre cohort study was performed on CD patients receiving **ustekinumab** between 2011 and 2016.

Cited by: 31

Author: C. Ma, R. N. Fedorak, G. G. Kaplan, L. A...

Publish Year: 2017

## Ustekinumab for the Treatment of Refractory Crohn's ...

<https://academic.oup.com/ibdjournal/article/22/7/1662/4562007> ▼

Jun 10, 2016 · Blocking the IL-12/IL-23 axis is proposed as a therapeutic target in several inflammatory disorders. 9, 10 Treatment with **ustekinumab** has been mostly investigated for moderate-to-severe psoriasis and psoriatic arthritis. 11, – 13 The **potential** beneficial effect of **ustekinumab** for other autoimmune **disease** such as multiple sclerosis is less ...

Cited by: 70

Author: Sam Khorrami, Daniel Ginard, Ignacio M...

Publish Year: 2016 Author: Khorrami, Sam

## Ustekinumab for the Treatment of Refractory Crohn's ...

[https://www.researchgate.net/publication/304008717\\_Ustekinumab\\_for\\_the\\_Treatment\\_of...](https://www.researchgate.net/publication/304008717_Ustekinumab_for_the_Treatment_of...)

**Ustekinumab** for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort Article in Inflammatory Bowel Diseases 22(7):1662-1669 · July 2016